AI Science Tracker
EN

Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

1 discovery from 2026

Discoveries

Automated full-process pipeline via multiparametric MRI for tumor segmentation, molecular subtype classification and prognostic factor analysis in breast cancer.

Source check: Source checked. Not independent scientific confirmation.

Finding: A multiparametric MRI pipeline combined 3D U-Net tumor segmentation with 2D ResNet biomarker classification in 484 breast-cancer patients across three institutions; the study reports validation including external performance measures. This is retrospective image-analysis validation, not prospective clinical benefit.

Technology: A 3D U-Net segments tumors from multiparametric MRI, and a 2D ResNet classifies molecular biomarkers from the resulting image features.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A 3D U-Net segments tumors from multiparametric MRI, and a 2D ResNet classifies molecular biomarkers from the resulting image features.
Test and result
Europe PMC abstract reports 484 patients at three institutions and validation with AUC/Dice measures; the exact metric values are omitted here.
Limitation / still unknown
Prospective clinical utility and treatment benefit were not evaluated; the reported external validation remains retrospective
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13247932/ · https://pubmed.ncbi.nlm.nih.gov/42273105/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.